WO2002066056A3 - Synthetic vaccines comprising polyhydroxypolymer carriers - Google Patents

Synthetic vaccines comprising polyhydroxypolymer carriers Download PDF

Info

Publication number
WO2002066056A3
WO2002066056A3 PCT/DK2002/000112 DK0200112W WO02066056A3 WO 2002066056 A3 WO2002066056 A3 WO 2002066056A3 DK 0200112 W DK0200112 W DK 0200112W WO 02066056 A3 WO02066056 A3 WO 02066056A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogens
polyhydroxypolymer
cell
carriers
coupled
Prior art date
Application number
PCT/DK2002/000112
Other languages
French (fr)
Other versions
WO2002066056A2 (en
WO2002066056A8 (en
Inventor
Klaus Gregorius Nielsen
Peter Koefoed
Original Assignee
Pharmexa As
Klaus Gregorius Nielsen
Peter Koefoed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2001/000113 external-priority patent/WO2001062284A2/en
Priority claimed from US09/785,215 external-priority patent/US7135181B2/en
Priority to IL15747502A priority Critical patent/IL157475A0/en
Priority to AU2002233166A priority patent/AU2002233166B2/en
Priority to JP2002565614A priority patent/JP2004529881A/en
Priority to EP02700174A priority patent/EP1363664A2/en
Application filed by Pharmexa As, Klaus Gregorius Nielsen, Peter Koefoed filed Critical Pharmexa As
Priority to NZ527720A priority patent/NZ527720A/en
Priority to CA002440197A priority patent/CA2440197A1/en
Publication of WO2002066056A2 publication Critical patent/WO2002066056A2/en
Publication of WO2002066056A3 publication Critical patent/WO2002066056A3/en
Priority to US10/643,103 priority patent/US20040191264A1/en
Publication of WO2002066056A8 publication Critical patent/WO2002066056A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides for novel immungens that are comprised of an activated polyhydroxypolymer backbone to which is attached 2 separate antigenic determinants. The 1st antigenic determinant includes a B-cell or CTL epitope and the 2nd antigenic determinant includes a T-helper epitope. In preferred embodiments, the antigenic determinants are derived from different molecules and species. Exemplary immunogens of the invention are constituted of a linear tresyl-activated dextran backbone to which is coupled B-cell or CTL epitopes of an antigen and to which is also coupled universal T-helper epitopes. Also disclosed are immunogenic compositions comprising the immunogens, methods of immunisation and a mehtod for identification of suitable immunogens of the invention.
PCT/DK2002/000112 2001-02-19 2002-02-19 Synthetic vaccines comprising polyhydroxypolymer carriers WO2002066056A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002440197A CA2440197A1 (en) 2001-02-19 2002-02-19 Synthetic vaccines comprising polyhydroxypolymer carriers
NZ527720A NZ527720A (en) 2001-02-19 2002-02-19 Synthetic vaccine agents
AU2002233166A AU2002233166B2 (en) 2001-02-19 2002-02-19 Synthetic vaccines comprising polyhydroxypolymer carriers
JP2002565614A JP2004529881A (en) 2001-02-19 2002-02-19 Synthetic vaccine agent
EP02700174A EP1363664A2 (en) 2001-02-19 2002-02-19 Synthetic vaccine agents
IL15747502A IL157475A0 (en) 2001-02-20 2002-02-19 Synthetic vaccines comprising polyhydroxypolymer carriers
US10/643,103 US20040191264A1 (en) 2001-02-19 2003-08-18 Synthetic vaccine agents

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
PCT/DK2001/000113 WO2001062284A2 (en) 2000-02-21 2001-02-19 Novel method for down-regulation of amyloid
DKPCT/DK01/00113 2001-02-19
US09/785,215 2001-02-20
US09/785,215 US7135181B2 (en) 2000-02-21 2001-02-20 Method for down-regulation of amyloid
DKPA200101231 2001-08-20
DKPA200101231 2001-08-20
US33754301P 2001-10-22 2001-10-22
US60/337,543 2001-10-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/643,103 Continuation-In-Part US20040191264A1 (en) 2001-02-19 2003-08-18 Synthetic vaccine agents

Publications (3)

Publication Number Publication Date
WO2002066056A2 WO2002066056A2 (en) 2002-08-29
WO2002066056A3 true WO2002066056A3 (en) 2003-01-03
WO2002066056A8 WO2002066056A8 (en) 2004-04-29

Family

ID=35160895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000112 WO2002066056A2 (en) 2001-02-19 2002-02-19 Synthetic vaccines comprising polyhydroxypolymer carriers

Country Status (10)

Country Link
EP (1) EP1363664A2 (en)
JP (1) JP2004529881A (en)
CN (1) CN100562338C (en)
AU (1) AU2002233166B2 (en)
CA (1) CA2440197A1 (en)
IL (1) IL157475A0 (en)
NO (1) NO335602B1 (en)
NZ (1) NZ527720A (en)
WO (1) WO2002066056A2 (en)
ZA (1) ZA200400895B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006504413A (en) * 2002-09-12 2006-02-09 ファーメクサ エイ／エス Immunization against autologous ghrelin
EP2481422A3 (en) * 2003-09-03 2013-04-03 Dendritherapeutics, Inc. Multiplex vaccines
US20070264280A1 (en) * 2003-11-07 2007-11-15 Federoff Howard J Compositions and Methods for Treating Neurological Diseases
WO2012125567A2 (en) * 2011-03-11 2012-09-20 Flow Pharma Inc. Vaccine formulation of mannose coated peptide particles
CN103665113A (en) * 2012-09-14 2014-03-26 深圳市安群生物工程有限公司 Human A beta 42 antigenic determinant polypeptide, human A beta 42 antigen, human A beta 42 antibody, application and kit
RU2635517C1 (en) * 2016-09-14 2017-11-13 Закрытое акционерное общество "Институт фармацевтических технологий" (ЗАО "ИФТ") Synthetic immunogen for protection and treatment of psychoactive substances addiction
CN112165956A (en) * 2018-04-10 2021-01-01 Ac免疫有限公司 Anti-abeta therapeutic vaccine
CA3095983A1 (en) 2018-04-10 2019-10-17 Ac Immune Sa Anti-abeta therapeutic vaccines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015760A1 (en) * 1992-02-11 1993-08-19 U.S. Government, As Represented By The Secretary Of The Army Dual carrier immunogenic construct
WO1993023076A1 (en) * 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
WO2000020027A2 (en) * 1998-10-05 2000-04-13 M & E Biotech A/S Methods for therapeutic vaccination

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015760A1 (en) * 1992-02-11 1993-08-19 U.S. Government, As Represented By The Secretary Of The Army Dual carrier immunogenic construct
WO1993023076A1 (en) * 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
WO2000020027A2 (en) * 1998-10-05 2000-04-13 M & E Biotech A/S Methods for therapeutic vaccination

Also Published As

Publication number Publication date
NO335602B1 (en) 2015-01-12
WO2002066056A2 (en) 2002-08-29
IL157475A0 (en) 2004-03-28
JP2004529881A (en) 2004-09-30
ZA200400895B (en) 2005-05-03
AU2002233166B2 (en) 2006-06-29
WO2002066056A8 (en) 2004-04-29
CA2440197A1 (en) 2002-08-29
CN1893970A (en) 2007-01-10
CN100562338C (en) 2009-11-25
NO20040431L (en) 2004-04-16
NZ527720A (en) 2005-03-24
EP1363664A2 (en) 2003-11-26

Similar Documents

Publication Publication Date Title
MY133780A (en) Vaccine composition
WO2004087204A3 (en) Microfluidized oil-in-water emulsions and vaccine compositions
HK1143950A1 (en) Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens
IL174413A0 (en) Immunological adjuvants compounds
WO2002072012A3 (en) A novel proteosome-liposaccharide vaccine adjuvant
WO2000057917A3 (en) Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
TW200600108A (en) Microfluidized oil-in-water emulsions and vaccine compositions
RU95105991A (en) Conjugate, vaccine, methods of immunogenicity enhancement, methods of immunization
WO2001039796A3 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2002026250A3 (en) Vaccines for proliferative ileitis
IL141868A0 (en) Novel methods for therapeutic vaccination
EP0755259A4 (en) CHIMERIC INFECTIOUS BURSAL DISEASE VIRUS cDNA CLONES, EXPRESSION PRODUCTS AND VACCINES BASED THEREON
DE60325696D1 (en) SYNTHESIS OF LIPOPOLYSACCHARIDE PROTEIN CONJUGATE VACCINES VIA THE LIPID A REGION AFTER REMOVING GLYCOSIDAL PHOSPHATESIS
WO2002066056A3 (en) Synthetic vaccines comprising polyhydroxypolymer carriers
WO2003024354A3 (en) Interleukin-12 as a veterinary vaccine adjuvant
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
WO2003049765A3 (en) Enveloped virus vaccine and method for production
WO2004078099A3 (en) Compositions and methods for the generation of protective immune response against malaria
ZA93216B (en) Vaccine containing acemannan as an adjuvant.
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
WO2001022994A3 (en) Vaccines against neisseria infection
DE69626642T2 (en) CETP FOR INCREASING THE HDL CHOLESTEROL CONTENT
DE69535059D1 (en) Borrelia burgdorferi bacterin
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
WO2002032455A3 (en) Vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2003/06422

Country of ref document: ZA

Ref document number: 10643103

Country of ref document: US

Ref document number: 200306422

Country of ref document: ZA

Ref document number: 2002565614

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002233166

Country of ref document: AU

Ref document number: 157475

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002700174

Country of ref document: EP

Ref document number: 527720

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 01362/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2440197

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002700174

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 35/2002 DUE TO A TECHNICAL PROBLEMAT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING UNDER (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION

WWP Wipo information: published in national office

Ref document number: 527720

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 527720

Country of ref document: NZ